The Cystic Fibrosis Foundation has awarded a milestone payment totaling $645,000 to Hollis-Eden Pharmaceuticals. The company earned the payment by meeting specific development milestones under an existing collaboration agreement with the Foundation to develop novel, anti-inflammatory therapies for people with CF.
| 1 min read
Share this article
TopicsAbout the CF Foundation | Drug Pipeline
CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug
News | 2 min read
CF Foundation Advocates to Protect Needs of People With CF in Post-Pandemic Medicaid Redeterminations
News | 5 min read
FDA Approves Kalydeco for Infants as Young as 1 Month
News | 4 min read
Stay up to date with The Foundation
Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.